Startseite
Kongressberichte 2021
ESMO Congress 2021
Friday, September 17
Mini oral sessions
Head and neck cancer, excl. thyroid
Head and neck cancer, excl. thyroid
860MO
Preoperative durvalumab (D) with or without tremelimumab (T) for resectable head and neck squamous cell carcinoma (HNSCC)
M.H. Hong, et al
Conclusions
These early data suggested that preoperative D+/-T was safe and feasible and had the potential to provide clinical benefits for patients with resectable HNSCC. The trial is ongoing and the updated outcomes with immune correlates will be presented with ESMO.
861MO
Spatial Distribution of CD8+ and FoxP3+ in a Window of Opportunity for Durvalumab (MEDI4736) plus Metformin Trial in Squamous Cell Carcinoma of the Head and Neck (HNSCC)
J.M. Curry, et al.
Conclusions
Greater pre-treatment mean CD8-FoxP3 distance and decreases in mean CD8-FoxP3 distances post-treatment were associated with pathologic response. Increased cytotoxic T-cell activity as determined by DSP were observed with therapy. This preliminary data suggests spatial analysis of T-cell subsets may be a biomarker for treatment response.
862MO
Gene expression profile differentiates short- and long-term survivors with immunotherapy in patients with recurrent/metastatic head and neck cancer
P. Bossi, et al.
Conclusions
These preliminary data indicate the presence of underlying differences in gene expression profiles between LTS and STS after treatment with ICI for platinum-refractory RM-HNSCC. These observations need further study and may have translational implications improving treatment selection.
863MO
Nomogram for Predicting Survival for Patients Receiving Definitive Chemoradiation in Locally Advanced Squamous Cell Carcinoma of the Head and Neck: A Secondary Analysis of NRG/RTOG 0129, 0522, and 1016
M.Z. Kharouta, et al.
Conclusions
Using a large cohort from 3 randomized trials of HNSCC patients receiving cisplatin-based chemoradiation, we developed internally and independently validated nomograms for prognostication of outcomes for individual patients using pretreatment clinical and patient characteristics. There was no association of sex with OS or PFS. To facilitate use and further validation of our nomograms, a free web-based tool is made available.
864MO
Role of geriatric assessment in tailoring treatment of locally advanced head and neck cancer: the ELDERLY study
P. Bossi, et al.
Conclusions
Geriatric intervention changed major therapeutic choices in about one out of 10 patients. In addition, CGA played an important role in tailoring elderly patients supportive care needs. Moreover, G8 can be used as a screening tool in LA-HNSCC, with a good sensitivity in identifying unfit patients who then need a complete geriatric evaluation, even if with limited specificity.
865MO
RMAC study: A randomized study evaluating the efficacy of metronomic adjuvant chemotherapy in patients with recurrent head and neck cancers post salvage surgery, not eligible for re-irradiation
N.S. Menon, et al.
Conclusions
The adjuvant 6-month metronomic chemotherapy schedule was ineffective in improving outcomes in recurrent head and neck cancer patients post salvage surgery who are not eligible for re-radiation.